CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study

This publication has 37 references indexed in Scilit:

• Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  New England Journal of Medicine, 2019
• Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
  Blood, 2018
• Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
  New England Journal of Medicine, 2017
• Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
  Blood, 2017
• Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function
  Cytotherapy, 2017
• Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
  Blood, 2015
• Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
  Journal of Clinical Oncology, 2014
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
  Journal of Clinical Investigation, 2011
• Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
  Blood, 2004
• Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
  New England Journal of Medicine, 1995